Peroxisome Proliferator-Activated Receptors (PPARs) were discovered by Isseman and Green in 1990 [1]. Since this time PPARs have been demonstrated to play a major role in a diverse group of processes and pathological conditions associated with aging [2, 3], inflammation [4, 5], immunity [6], obesity [7], diabetes [8], cancer [9], and fertility [10, 11].
In the short period since their discovery, interest in the functioning of the PPAR receptors has greatly intensified, and studies of the biology of the PPARs have become abundant. Accordingly, the number of publications in this field has undergone exponential growth, climbing from less than 100 published articles in 1995 to more than 1600 articles in 2005; continued growth is to be expected. Of further importance, the PPARs have entered directly into the clinical arena. Drugs which activate PPARs are currently used clinically to treat diabetes, and others are also undergoing clinical trials as anti-inflammatory agents.
PPAR Research is designed to be a much needed, open access forum dedicated to the publication of original, high-quality, peer-reviewed articles on the advances in basic research, preclinical studies, and clinical trials involving PPARs, and their obligatory heterodimer partners, retinoid-X receptors. This Journal will provide a unique venue to bring together a diverse scope of studies and will offer to both scientists and clinicians working in this field of study the opportunity to learn of the latest discoveries in areas other than their own.
PPAR Research also intends to illustrate the magnitude and significance of this discipline by bringing into focus the diversity of areas of study involved in PPAR research. This will surely promote interest in as well as enhanced understanding of this critical field of research by the scientific community at large.
References
- 1.Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347(6294):645–650. doi: 10.1038/347645a0. [DOI] [PubMed] [Google Scholar]
- 2.Cheng PT, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases. Mini Reviews in Medicinal Chemistry. 2005;5(8):741–753. doi: 10.2174/1389557054553758. [DOI] [PubMed] [Google Scholar]
- 3.Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Current Opinion in Investigational Drugs. 2004;5(9):936–940. [PubMed] [Google Scholar]
- 4.Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology. 2001;169(3):453–459. doi: 10.1677/joe.0.1690453. [DOI] [PubMed] [Google Scholar]
- 5.Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. European Journal of Pharmacology. 2004;483(1):79–93. doi: 10.1016/j.ejphar.2003.10.056. [DOI] [PubMed] [Google Scholar]
- 6.Schlezinger JJ, Howard GJ, Hurst CH, et al. Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin J2. Journal of Immunology. 2004;173(5):3165–3177. doi: 10.4049/jimmunol.173.5.3165. [DOI] [PubMed] [Google Scholar]
- 7.Zhang F, Lavan B, Gregoire FM. Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News & Perspectives. 2004;17(10):661–669. doi: 10.1358/dnp.2004.17.10.873918. [DOI] [PubMed] [Google Scholar]
- 8.Patsouris D, Muller M, Kersten S. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Current Opinion in Investigational Drugs. 2004;5(10):1045–1050. [PubMed] [Google Scholar]
- 9.Tien ES, Gray JP, Peters JM, Vanden Heuvel JP. Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes. Cancer Research. 2003;63(18):5767–5780. [PubMed] [Google Scholar]
- 10.Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reproductive Biology and Endocrinology. 2005;3:41. doi: 10.1186/1477-7827-3-41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Corton JC, Lapinskas PJ. Peroxisome proliferator-activated receptors: mediators of phthalate ester-induced effects in the male reproductive tract? Toxicological Sciences. 2005;83(1):4–17. doi: 10.1093/toxsci/kfi011. [DOI] [PubMed] [Google Scholar]